Pyruvate Dehydrogenase Kinases: Therapeutic Targets for Diabetes and Cancers

被引:75
作者
Jeoung, Nam Ho [1 ]
机构
[1] Catholic Univ Daegu, Coll Med Sci, Dept Pharmaceut Sci & Technol, 13-13 Hayang Ro, Hayang Eup 712702, Gyeongsan, South Korea
关键词
Diabetes mellitus; type; 2; Glucose metabolism; Pyruvate dehydrogenase complex; Pyruvate dehydrogenase kinase; Pyruvate dehydrogenase kinase inhibitor; Warberg effect; METABOLIC SWITCH; DRUG-RESISTANCE; SKELETAL-MUSCLE; FATTY-ACIDS; RAT-HEART; IN-VITRO; HYPOXIA; DICHLOROACETATE; MECHANISMS; GLUCOSE;
D O I
10.4093/dmj.2015.39.3.188
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Impaired glucose homeostasis is one of the risk factors for causing metabolic diseases including obesity, type 2 diabetes, and cancers. In glucose metabolism, pyruvate dehydrogenase complex (PDC) mediates a major regulatory step, an irreversible reaction of oxidative decarboxylation of pyruvate to acetyl-CoA. Tight control of PDC is critical because it plays a key role in glucose disposal. PDC activity is tightly regulated using phosphorylation by pyruvate dehydrogenase kinases (PDK1 to 4) and pyruvate dehydrogenase phosphatases (PDP1 and 2). PDKs and PDPs exhibit unique tissue expression patterns, kinetic properties, and sensitivities to regulatory molecules. During the last decades, the up-regulation of PDKs has been observed in the tissues of patients and mammals with metabolic diseases, which suggests that the inhibition of these kinases may have beneficial effects for treating metabolic diseases. This review summarizes the recent advances in the role of specific PDK isoenzymes on the induction of metabolic diseases and describes the effects of PDK inhibition on the prevention of metabolic diseases using pharmacological inhibitors. Based on these reports, PDK isoenzymes are strong therapeutic targets for preventing and treating metabolic diseases.
引用
收藏
页码:188 / 197
页数:10
相关论文
共 50 条
  • [41] Investigation of the role of Ras and other signaling kinases on the regulation of pyruvate dehydrogenase complex activity
    Antonio Garcia-Trinidad
    Nicky Whalley
    Susan Critchlow
    Cancer & Metabolism, 2 (Suppl 1)
  • [42] Stress-activated kinases as therapeutic targets in pancreatic cancer
    Traub, Benno
    Roth, Aileen
    Kornmann, Marko
    Knippschild, Uwe
    Bischof, Joachim
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (30) : 4963 - 4984
  • [43] Neuropilins: relevant therapeutic targets to improve the treatment of cancers
    Dumond, Aurore
    Demange, Luc
    Pages, Gilles
    M S-MEDECINE SCIENCES, 2020, 36 (05): : 487 - 496
  • [44] Blocking Aerobic Glycolysis by Targeting Pyruvate Dehydrogenase Kinase in Combination with EGFR TKI and Ionizing Radiation Increases Therapeutic Effect in Non-Small Cell Lung Cancer Cells
    Dyrstad, Sissel E.
    Lotsberg, Maria L.
    Tan, Tuan Zea
    Pettersen, Ina K. N.
    Hjellbrekke, Silje
    Tusubira, Deusdedit
    Engelsen, Agnete S. T.
    Daubon, Thomas
    Mourier, Arnaud
    Thiery, Jean Paul
    Dahl, Olav
    Lorens, James B.
    Tronstad, Karl Johan
    Rosland, Gro V.
    CANCERS, 2021, 13 (05) : 1 - 28
  • [45] High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity
    Wu, Dong-Mei
    Wang, Yong-Jian
    Fan, Shao-Hua
    Zhang, Zi-Feng
    Shan, Qun
    Lu, Jun
    Chen, Gui-Quan
    Zheng, Yuan-Lin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 164 : 252 - 262
  • [46] The pyruvate dehydrogenase complex in cancer: An old metabolic gatekeeper regulated by new pathways and pharmacological agents
    Saunier, Elise
    Benelli, Chantal
    Bortoli, Sylvie
    INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (04) : 809 - 817
  • [47] Furoates and thenoates inhibit pyruvate dehydrogenase kinase 2 allosterically by binding to its pyruvate regulatory site
    Masini, Tiziana
    Birkaya, Barbara
    van Dijk, Simon
    Mondal, Milon
    Hekelaar, Johan
    Jager, Manuel
    van Scheltinga, Anke C. Terwisscha
    Patel, Mulchand S.
    Hirsch, Anna K. H.
    Moman, Edelmiro
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2016, 31 : 170 - 175
  • [48] Dichloroacetate, a pyruvate dehydrogenase kinase inhibitor, ameliorates type 2 diabetes via reduced gluconeogenesis
    Katayama, Yuko
    Kawata, Yayoi
    Moritoh, Yusuke
    Watanabe, Masanori
    HELIYON, 2022, 8 (02)
  • [49] Microenvironmental control of glucose metabolism in tumors by regulation of pyruvate dehydrogenase
    Golias, Tereza
    Kery, Martin
    Radenkovic, Silvia
    Papandreou, Ioanna
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (04) : 674 - 686
  • [50] The Pyruvate Dehydrogenase Complex in Sepsis: Metabolic Regulation and Targeted Therapy
    Zeng, Zhenhua
    Huang, Qiaobing
    Mao, Liangfeng
    Wu, Jie
    An, Sheng
    Chen, Zhongqing
    Zhang, Weijin
    FRONTIERS IN NUTRITION, 2021, 8